Company intelligence / Profile preview

Pike Pharma

United States

Ownership: Private
Development stage: Other

Overview

Pike Therapeutics has demonstrated positive pharmacokinetic results in a rabbit study for its weekly CBD transdermal patch, achieving sustained blood levels equivalent to oral dosing with lower exposure and potential for improved tolerability in epilepsy indications.

Therapeutic areas: Neurology
Modalities: Transdermal delivery
Industry: Biotech

Partnerships

Transdermal Research Pharm Laboratories LLC (TRPL)

Beyond the preview

Go deeper on Pike Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pike Pharma.

Explore the full profile